• Global Biosimilars Week 2024
    Advance Access to Biosimilars
    Join IGBA’s 5th Global Biosimilars Week from November 11–15, 2024! This online campaign aims to raise awareness about the impact of biosimilar medicines. We encourage patients, healthcare professionals, and organizations to share resources using the hashtag #GlobalBiosimilarsWeek. Together, let’s enhance access to these vital treatments!
  • The Next Frontier for Accessible Medicines
    How Can We Improve Access and Affordability for Medicines and Treatments?
    Atlantic staff will join experts to discuss the importance of generics and biosimilars and challenges in the industry. November 13, 2024, Washington D.C.
  • 2024 AAM Generic & Biosimilar Medicines Savings Report
    2024 U.S. Generic & Biosimilar Medicines Savings Report
    Generic and biosimilar medicines saved $445 billion in 2023. Representing 90 percent of prescriptions filled but only 13 percent of spending, generics and biosimilars are an integral part of the U.S. healthcare system. However, the sustainability of this industry remains fragile.
  • Hatch-Waxman 40 Years
    AAM White Paper: Hatch-Waxman Turns 40
    “Since the introduction of this law, we have all seen incredible savings. But even as we celebrate the success of forty years of Hatch-Waxman, those savings, the increased patient access, and a model of generic adoption that leads the world, are at risk.” —David Gaugh, Interim President & CEO, AAM.
  • Access! AAM Annual Meeting 2025
    Join Us at Access! 2025
    AAM’s annual meeting unites policymakers, influential speakers, and industry leaders to shape the future of generics and biosimilars. Engage in discussions about the business, breakthroughs, and politics that drive our industry. This is your chance to hear from world-renowned speakers and gain insights into the future of our field. February 3–5, 2025, at Amelia Island, FL.
  • Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?
    Avalere analysis finds Part D prescription drug plans continue to increase patient copays for generics by moving them to higher tiers.

Recent Updates

Video
Aug 6, 2020 | Erica Klinger
The Generic and Biosimilar Industry Has a Plan to Secure Our Medicines
Video
Aug 5, 2020 | Erica Klinger
AAM Interim CEO Jeff Francer: New Opportunities at the GRx+Biosims 2020 Virtual Conference
Video
Jul 31, 2020 | Erica Klinger
COVID-19 Response: Steve Giuli at Apotex

Our Brands and Campaigns

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.